Importantly, this study found that treatment with C. butyricum can change the metabolites of microorganisms, such as secondary bile acids and SCFAs, and activate the G protein-coupled receptors GPR43 and GPR109A to inhibit the development and progression of CRC (Figure 3). The gene discussed is HCAR2; the disease is colorectal carcinoma.